2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3511 Epigenomic profiling of Epstein-Barr virus (EBV) CpG DNA methylation in clinical features and outcomes of EBV+ post-transplant lymphoproliferative disease.

Megan Stewart, BS, Haley Lynn Klimaszewski, BS2, Timothy J Voorhees, MD,MSc3, Christopher C Oakes, PhD4, Christoph Weigel, PhD5, Robert A Baiocchi, MD, PhD6
1 The Ohio State University College of Medicine, Columbus, Ohio, United States, The Ohio State University Heart and Lung Research Institute, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University Wexner Medical Center, Columbus, United States, The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University College of Medicine, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University Division of Hematology, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University Division of Hematology, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University Division of Hematology, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University Division of Hematology, Columbus, Ohio, United States, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States

Introduction: Post-transplant lymphoproliferative disease (PTLD) is a complication of iatrogenic immunosuppression in solid organ and stem cell transplant recipients. The majority of cases are associated with the oncogenic Epstein-Barr virus (EBV). EBV exists in either a lytic (infectious) or latent (dormant) state. During latency, EBV resides in B cells, evades host immune surveillance and establishes lifelong persistence. While quantitative PCR (viral load) is the current standard method of monitoring EBV infection in vulnerable patients, limitations in discerning the nature of the EBV disease state exist. DNA methylation of the EBV genome holds potential to better understand the oncogenic life cycle, but this has yet to be applied to EBV+ PTLD samples. Reduction of immunosuppression (RIS), with or without rituximab, is the standard frontline therapy for EBV+ PTLD. However, a substantial proportion of patients fail frontline management, requiring cytotoxic chemotherapy. Biomarkers predicting treatment response remain limited. We hypothesized that EBV epigenomic DNA methylation patterns could inform disease pathogenesis and clinical outcomes in patients with EBV+ PTLD.

Methods: We performed a retrospective chart review of EBV+ transplant recipients treated at The Ohio State University between 1997 and 2026. Clinical variables included transplant characteristics, histopathology, EBV viral load, immunosuppressive and treatment regimen, radiographic response, progression-free survival and overall survival (OS). Patients were categorized into four clinical groups: EBV reactivation that never progressed to PTLD (n=17), PTLD responding to RIS with or without rituximab (n=44), PTLD requiring immunochemotherapy following failure of RIS/rituximab and achieving response (n=20) and PTLD progressing despite immunochemotherapy (n=13). We isolated and bisulfite converted cell-free EBV DNA from plasma then used a multiplex hybrid PCR-mass spectrometry methylation assay (iPLEX) to target 35 EBV CpGs, covering regions associated with lytic (BZLF1, BRLF1) and latent (LMP1, Qp) activity. DNA methylation at each CpG was compared across the four clinical groups.

Results: Of 94 transplant patients, 77 were diagnosed with PTLD. Mean age at diagnosis was 50 years. There were no differences in age at transplant or PTLD diagnosis, race or sex between the four clinical groups described in the methods (p>0.1). Types of organ transplants were as follows: 62% kidney, 15% liver, 11% stem cell, 6% pancreas, 3% heart and 3% lung. Unsupervised clustering of methylation data yielded four distinct methylation signatures: low (<35% average methylation), high (>60%) and intermediate-I and -II, differentiated by unique methylation patterns. Low methylation was almost exclusively found in patients with EBV reactivation (p<0.001). Median methylation was 24% in patients with EBV reactivation compared with 59% in those with PTLD, representing a significant increase in methylation associated with PTLD development (p=0.005). Associations of EBV methylation signatures and EBV viral load with treatment response and OS were compared to assess benefit over the current standard. EBV viral load was not associated with treatment response (p=0.98), unlike EBV methylation signatures. The distributions of methylation signatures differed significantly among patients with EBV reactivation, RIS/rituximab responders, immunochemotherapy responders and immunochemotherapy progressors (p<0.001). Patients with EBV reactivation were significantly enriched for low methylation (p<0.001). Contrarily, RIS/rituximab responders were enriched for intermediate-I (p=0.001), whereas immunochemotherapy progressors were enriched for intermediate-II (p<0.05) and high (p<0.05) methylation. No individual methylation signature was significantly enriched among immunochemotherapy responders. While EBV viral load at the time of diagnosis was not associated with OS (p=0.18), patients with intermediate-I methylation demonstrated significantly longer OS (13.2 years) than those with intermediate-II and high methylation (4.3 and 1.7 years, p<0.001).

Conclusion: EBV DNA methylation state clearly distinguished non-malignant EBV reactivation from EBV+ PTLD, outperforming EBV viral load. Additionally, it was associated with OS and response to treatment in EBV+ PTLD. We underscore the utility of measuring EBV methylation in cell-free DNA from plasma as a potential novel biomarker for transplant care.

Megan Stewart, BS: No relevant conflicts of interest to declare.